Results 181 to 190 of about 212,304 (319)

Genetically modified animals in the food and pharmaceutical chains: economics, public perception and policy implications [PDF]

, 2012
Cristina Mora, Davide Menozzi, L.H. Aramyan, N.I. Valeeva, G. Pakky Reddy, K.L. Zimmermann, Mora, Cristina, Menozzi, Davide, Aramyan, Lusine H., Valeeva, Natasha I., Pakky, R., Zimmermann, Karin L.   +11 more
openalex   +1 more source

Human Capital Robotic Integration and Value Creation for Organizations

Journal of Organizational Behavior, EarlyView.
ABSTRACT Due to rapid advancements in artificial intelligence and machine learning, the research conversation has drifted from viewing robots as replacements for humans (i.e., the substitute view) to a view that considers the possible benefits of human–robot collaboration in the workplace (i.e., the complementary view).
Chou‐Yu Tsai, Jason D. Marshall, Rory Eckardt, Shelley D. Dionne, Malte F. Jung, YoYo Tsung‐Yu Hou, Biying Yang   +6 more
wiley   +1 more source

Correction: The unexploited potential of data systems tracking medicines utilization: an opportunity to improve access to oncology combination therapies. [PDF]

Front Pharmacol
Simoens S, Dodwell D, Hartevelt M, Lindgren P, Pistollato M, Pont LG, Pontes C, Roediger A, Sablek A, Van Ganse E, Wang Q, Wenger C, Wilsdon T, Xoxi E, Godman B.   +14 more
europepmc   +1 more source

Economics of the pharmaceutical industry [PDF]

, 2006
Danzon, Patricia M.
core  

Second‐Order Between‐Supplier Learning

Journal of Operations Management, EarlyView.
ABSTRACT Substantial empirical evidence shows that suppliers in emerging economies can enhance their technological capabilities through direct learning from technologically advanced foreign competitors. However, suppliers in emerging markets may struggle to learn directly from knowledge about competitors’ products that are not widely available on the ...
Lisha Liu, Xianwei Shi, Guangzhi Shang
wiley   +1 more source

Economic Markets and Pharmaceutical Innovation

Journal of Economic Perspectives
Pharmaceutical innovations reach the market after a long and risky process that requires large, fixed, and sunk investments. Governments provide incentives for firms to make these investments through various forms of intellectual property protection that attempt to provide a return on capital for investors.
openaire   +1 more source

The Southern California Healthcare Delivery Science Center: A Model for Aligning Patients, Healthcare Systems, and Researchers to Develop, Test, and Disseminate Innovations to Achieve Health Equity

Learning Health Systems, EarlyView.
ABSTRACT Introduction A key barrier to translating evidence into practice is the paucity of learning health system (LHS) researchers elucidating and addressing barriers to implementation and maintenance. Methods In response to the growing need for a workforce dedicated to translating evidence into practice, we developed the Southern California ...
Amytis Towfighi, Aidan R. Lindgren, Thomas A. Buchanan, Hal F. Yee Jr, Allison Orechwa   +4 more
wiley   +1 more source

Impact of Chinese national centralized volume-based drug procurement policy on health costs and utilization: An interrupted time series analysis using panel data (2009-2022). [PDF]

PLoS One
Jiang Y, Wan G, Shi Y, Pu G, Shao X.
europepmc   +1 more source

Substitute economics and the threat of artificial intelligence providing pharmaceutical care

T. Joseph Mattingly
openalex   +1 more source

The economics of pharmaceuticals and health sector reform in the Americas [PDF]

, 1998
Yvette Madrid, Germán Velásquez, Enrique Fefer   +2 more
openalex   +1 more source